Straits Times Index
3,303.19 +10.26 (+0.31%) S&P 500
5,180.74 +52.95 (+1.03%) Dow
38,852.27 +176.59 (+0.46%) Nasdaq
16,349.25 +192.92 (+1.19%) Bitcoin USD
63,492.39 -279.06 (-0.44%) CMC Crypto 200
1,364.74 +52.11 (+3.97%)
Supernus Pharmaceuticals Inc (S49.SG)
| Previous close | 28.20 |
| Open | 28.20 |
| Bid | 28.20 x 150000 |
| Ask | 28.80 x 150000 |
| Day's range | 28.00 - 28.20 |
| 52-week range | 20.80 - 33.20 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Benzinga
Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's Disease
On Monday, Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) announced a regulatory update for SPN-830, an investigational apomorphine infusion device under FDA review for the continuous treatment of motor fluctuations (“off” episodes) in Parkinson’s disease (PD). The FDA has issued a Complete Response Letter (CRL) in response to the company’s New Drug Application (NDA) for SPN-830. The CRL indicates that the review cycle for the application is complete but that the application still needs to be prepa
- Insider Monkey
11 Best Small Cap Pharma Stocks to Invest In
In this piece, we will take a look at the 11 best small cap pharma stocks to invest in. If you want to skip our overview of the global pharmaceutical and healthcare industry, which is one the most unique sectors in the world, then you can check out 5 Best Small Cap Pharma Stocks to […]
- Simply Wall St.
Supernus Pharmaceuticals Full Year 2023 Earnings: Beats Expectations
Supernus Pharmaceuticals ( NASDAQ:SUPN ) Full Year 2023 Results Key Financial Results Revenue: US$607.5m (down 8.9...
